- **Pregnancy:**Trastuzumab is believed to be a human teratogen. Fetal exposure has been associated with the development of oligohydramnios, leading to pulmonary hypoplasia and death. Patients of childbearing potential should use at least one form of contraception while receiving trastuzumab. It is unknown if trastuzumab is secreted in human breast milk.

- **Cardiac Dysfunction:**Due to the risk of cardiotoxicity, trastuzumab should be used with extreme caution in patients with pre-existing structural heart disease.